查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1355209

數位病理市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按產品類型、按應用、最終用戶、地區和競爭細分

Digital Pathology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented By Product Type, By Application, By End User, By Region and Competition
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2022 年全球數位病理學市場估值為 9.3 億美元，預計到 2028 年預測期內將強勁成長，複合年成長率為 10.19%。數位病理學是一個專注於從數位化標本載玻片中提取資料的專業領域。透過利用基於電腦的技術和虛擬顯微鏡，數位病理學能夠獲取基於影像的資訊。這種創新方法顯著提高了全球病理實驗室的效率、工作流程和收入。透過將載玻片轉換為數位對應物，使用者可以在電腦顯示器上輕鬆管理、分享、檢視和分析它們。數位病理學在多個領域都有應用，包括原發性疾病診斷、診斷決策支援、術中診斷、診斷諮詢、住院醫師和醫療培訓、同行評審、手動和半定量免疫組織化學(IHC) 審查以及臨床研究。它的實施提高了實驗室效率並加快了診斷結果。隨著教育部門、藥物開發、組織研究和疾病診斷的持續支持，數位病理學作為醫療保健領域一項重要且經過驗證的技術正在迅速獲得認可。

主要市場促進因素

提高實驗室效率

市場概況
預測期 2024-2028
2022 年市場規模 9.3億美元
2028 年市場規模 16.5億美元
2023-2028 年複合年成長率 10.19%
成長最快的細分市場 疾病診斷
最大的市場 北美洲

數位病理學透過減少週轉時間、降低成本並向具有主題專業知識的用戶提供全面的詳細資訊來提高效率。提高實驗室結果至關重要，因為醫生和患者嚴重依賴實驗室結果進行疾病診斷和治療。數位病理學允許快速遠端存取病理影像，從而實現醫療保健專業人員之間更快的協作。病理學家和專家可以不受物理距離的限制審查病例並提供諮詢，從而可能更快地做出診斷和治療決策。傳統病理學涉及準備和運輸物理載玻片，這可能既耗時又昂貴。借助數位病理學，可以減少與玻片製作、運輸、儲存和檢索相關的費用。對準確、高效、及時的實驗室結果的需求不斷成長，推動了數位病理市場的成長。

科技的快速進步

數位病理系統的快速進步預計將推動市場成長。數位成像、電腦化、機器人光學顯微鏡和光纖通訊都在這一擴張中發揮重要作用。全玻片成像是一種比傳統光學顯微鏡具有眾多優勢的技術，預計將對市場產生正面影響。此外，微陣列和各種預測模型（例如混合模型和 API 演算法）的發展預計將進一步加速數位影像分析的市場成長。人們越來越喜歡電腦輔助診斷，它整合了影像處理、物理、數學和計算演算法，有助於有效的疾病檢測，並能夠評估感興趣的解剖結構、疾病進展和風險評估。

人工智慧在醫療保健領域的應用不斷增加

人工智慧在醫療保健中的應用不斷增加，人們越來越關注透過將人工智慧整合到包括病理診斷在內的不同醫療保健服務中來提高患者護理品質。 AI演算法可以快速且準確地分析大量病理影像。它們可以幫助病理學家檢測異常、識別模式並提供更精確的診斷，最終導致更快的治療決策並改善患者的治療結果。人工智慧可以透過提供客觀、一致的分析來幫助減少病理診斷中的人為錯誤和變異性。這對於可能錯過細微特徵的複雜情況尤其有價值。透過將患者資料與人工智慧見解相結合，病理學家和臨床醫生可以為個別患者量身定做治療計劃，最佳化治療方法並最大程度地減少不必要的干涉。因此，人工智慧 (AI) 有助於簡化初級保健流程和自動化，使醫生能夠優先考慮病情更危重的患者。此外，醫療保健產業的人工智慧解決方案正在逐步採用更以人為本的方法。

癌症盛行率增加

根據世界衛生組織的數據，2018 年全球有 960 萬人死亡，新增 1,810 萬癌症病例，這是史無前例的。全球人口老化和久坐生活方式的加劇導致癌症病例數量不斷增加。該聯合國組織預測，到2050年，老年人數量將達到近21億。使用動物模型和臨床試驗進行的臨床前研究在確定藥物的安全性和有效性方面發揮著至關重要的作用。數位病理學具有多種優勢，例如降低錯誤風險、儲存藥物資料、將資料整合到電子健康記錄 (EHRS) 以及評估患者對特定藥物的反應。由於對藥物開發和藥物發現研發的日益關注，全球數位病理學產業正在經歷成長，導致臨床和臨床前試驗的增加。對癌症等慢性病更快診斷工具的需求以及提高工作流程生產力的需求是促進因素。此外，越來越多的老年人口更容易患慢性病，預計將進一步增加對先進技術診斷程序的需求。

主要市場挑戰

數位病理學的高成本

數位病理學的高成本以及新興和不已開發國家的低採用率阻礙了市場的成長。 Augmenting 透過提供具有整合數位病理軟體應用程式的模組化硬體平台來應對這項挑戰，有助於降低成本。實施數位病理系統需要在掃描器、儲存基礎設施和軟體解決方案方面進行大量前期投資。與載玻片數位化、維護數位檔案和培訓人員相關的費用可能很大，特別是對於預算有限的小型實驗室或醫療機構。此外，將數位病理學整合到現有實驗室工作流程以及 IT 支援和基礎設施升級的需求可能會給一些組織帶來挑戰。

監管和標準化挑戰

數位病理學的採用受到不同地區不同監管要求和標準的影響。數位病理系統和軟體的驗證和監管批准可能是一個複雜且耗時的過程。此外，在數位病理影像的傳輸和儲存過程中，解決與資料隱私、安全性和遵守病患保密法規相關的挑戰至關重要。在數位病理解決方案用於臨床診斷之前，通常需要經過嚴格的驗證過程，以證明其準確性、可靠性和安全性。不同地區的監管機構批准這些技術的標準可能不同。病患資料安全和隱私在醫療保健中至關重要。數位病理系統必須遵守嚴格的資料保護法規，例如美國的健康保險流通和責任法案（HIPAA）和歐盟的一般資料保護規範（GDPR）。

主要市場趨勢

遠距病理學和遠距會診

遠距病理學的日益普及使得遠距診斷和諮詢成為可能，使病理學家能夠協作並提供專家意見，而不受地理限制。遠距病理學在 COVID-19 大流行期間獲得了顯著的重視，因為它促進了遠距工作並最大限度地降低了病理學家的暴露風險。例如，病理學家可以與同事遠端審查和討論病例，參與多學科腫瘤委員會，或為服務不足的地區或面臨病理學專業知識短缺的地區提供諮詢。人們越來越傾向於整合影像處理、物理、數學和計算演算法的電腦輔助診斷，有助於有效的疾病檢測。它還有助於評估感興趣的解剖結構、量化疾病進展和風險評估，從而刺激市場成長。值得注意的是，奧林巴斯等公司提供了一系列用於遠端幻燈片共享和影像處理的工具，有助於預計未來幾年的市場擴張。 2020 年 4 月，徠卡生物系統公司的 Aperio AT2 DX 掃描儀和 Aperio WebViewer 獲得 FDA 批准，從而在大流行期間實現遠端診斷。此外，在這次緊急情況下，飛利浦的 IntelliSite 病理學解決方案還獲得了 FDA 的批准，進一步支持遠端診斷。

人工智慧和機器學習的分析整合

將人工智慧（AI）和機器學習演算法涵蓋數位病理平台是一個重要的新興趨勢。人工智慧有能力協助病理學家完成各種任務，包括自動組織識別、異常檢測、生物標記量化和疾病結果預測。這些技術在提高病理診斷的效率、準確性和可重複性方面具有巨大潛力。例如，人工智慧演算法可以幫助癌細胞的自動檢測和分類，以及組織病理學影像中特定特徵的識別。

細分市場洞察

應用洞察

由於慢性病盛行率不斷上升，預計疾病診斷領域在預測期內將顯著成長。數位病理學涵蓋一系列疾病診斷技術，包括實驗室管理系統、數位聽寫、儀表板和工作流程控制、數位影像分析、電子標本標籤和監測以及概要報告工具。製造商目前專注於開發新穎且快速的診斷技術。數位科技的整合增強了診斷過程的每個階段，並促進部門內部和部門之間的無縫資訊交換。

最終使用者見解

製藥和生物技術公司代表了最終用戶全球數位病理學需求的最大部分。該細分市場的巨大佔有率和快速成長速度可歸因於多種因素。其中包括在藥物發現研究和藥物毒理學研究中擴大利用數位病理學。此外，生物技術公司利用數位病理學來開發生物樣本庫、生物製藥試驗、分子測定和個人化醫療。

區域洞察

由於持續的研發投資、政府支援技術先進系統的舉措、數位影像的日益普及以及知名企業的參與，北美佔據了最大的市場佔有率。在北美，在專注於數位病理學研究和影像分析增強​​工具開發的公司的推動下，美國成為市場領導者。數位病理學在疾病診斷中的加速應用，加上美國有利的報銷政策，預計將推動該地區的成長並提高癌症診斷的標準。數位病理學在教育和培訓中的日益普及，以及人工智慧與數位病理系統的整合，是推動區域市場成長的關鍵因素。

對數位病理學項目、教育和培訓項目的支持不斷增加，推動了歐洲市場的成長。癌症發病率上升、英國擴大採用數位病理學解決方案以及德國會議數量不斷增加等因素也促成了這一成長。數位病理學涉及掃描玻片以產生虛擬影像，該影像與臨床資料一起為病理學家提供癌症患者的綜合影像。這使得額外的診斷程序成為可能，包括影像分析研究，這是傳統玻片無法實現的。英國數位病理學的採用率很高，預計未來幾年將進一步擴大。此外，英國的病理學家表示需要數位病理學解決方案的指導、培訓和教育。隨著英國癌症發病率的增加，該國的數位病理市場預計將在預測期內擴大。

主要市場參與者

  • 3DHISTECH
  • 科里斯塔
  • 艾福利亞科技有限公司
  • 阿科亞生物科學公司
  • 光掃描
  • 格倫科軟體
  • QProscia公司
  • 坎特龍系統公司
  • 微掃描技術公司

報告範圍：

數位病理學市場，按產品類型：

  • 掃描儀
  • 軟體
  • 儲存和通訊系統

數位病理學市場，按應用：

  • 疾病診斷
  • 遠距會診
  • 藥物發現
  • 培訓與教育

數位病理學市場，按最終用戶分類：

  • 製藥與生物技術公司
  • 醫院和診所
  • 學術機構與研究實驗室

數位病理學市場，按地區：

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 法國
    • 英國
    • 義大利
    • 德國
    • 西班牙
  • 亞太
    • 中國
    • 印度
    • 日本
    • 澳洲
    • 韓國
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特
    • 土耳其
    • 埃及

競爭格局

公司概況：全球數位病理市場主要公司的詳細分析。

可用的客製化：

全球數位病理學市場報告以及給定的市場資料，技術科學研究根據公司的具體需求提供客製化服務。該報告可以使用以下自訂選項：

公司資訊

  • 其他市場參與者（最多五個）的詳細分析和概況分析。

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：客戶之聲

第 5 章：全球數位病理市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品類型（掃描器、軟體以及儲存和通訊系統）
    • 按應用（疾病診斷、遠距諮詢、藥物發現、培訓和教育）
    • 按最終用戶（製藥和生物技術公司、醫院和診所、學術機構和研究實驗室）
    • 按地區
    • 按公司分類 (2022)
  • 市場地圖

第 6 章：北美數位病理市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品類型
    • 按應用
    • 按最終用戶
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第 7 章：歐洲數位病理市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品類型
    • 按應用
    • 按最終用戶
    • 按國家/地區
  • 歐洲：國家分析
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙

第 8 章：亞太地區數位病理市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品類型
    • 按應用
    • 按最終用戶
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第 9 章：南美洲數位病理市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品類型
    • 按應用
    • 按最終用戶
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲數位病理市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品類型
    • 按應用
    • 按最終用戶
    • 按國家/地區
  • MEA：國家分析
    • 南非數位病理學
    • 沙烏地阿拉伯數位病理學
    • 阿拉伯聯合大公國數位病理學

第 11 章：市場動態

第 12 章：市場趨勢與發展

第 13 章：全球數位病理學市場：SWOT 分析

第14章：競爭格局

  • 商業概覽
  • 應用程式產品
  • 最近的發展
  • 主要人員
  • SWOT分析
    • 3DHISTECH
    • Corista
    • Aiforia Technologies Oy
    • Akoya Biosciences
    • OptraSCAN
    • Glencoe Software
    • QProscia Inc
    • Kanteron Systems
    • Mikroscan Technologies

第 15 章：策略建議

第 16 章：關於我們與免責聲明

簡介目錄
Product Code: 1615

Global Digital Pathology Market was valued at USD 0.93 billion in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 10.19% through 2028. Digital pathology is a specialized field that focuses on extracting data from digitized specimen slides. By utilizing computer-based technology and virtual microscopy, digital pathology enables the acquisition of image-based information. This innovative approach has significantly enhanced the efficiency, workflow, and revenue of pathology labs worldwide. Through the conversion of glass slides into digital counterparts, users can effortlessly manage, share, view, and analyze them on a computer monitor. Digital pathology finds applications in various areas, including primary disease diagnosis, diagnostic decision support, intraoperative diagnosis, diagnostic consultation, resident and medical training, peer review, manual and semi-quantitative immunohistochemistry (IHC) review, and clinical research. Its implementation has led to improved laboratory efficiency and faster diagnostic results. With growing support from the education sector, drug development, tissue-based research, and disease diagnosis, digital pathology is rapidly gaining recognition as an essential and proven technology in the healthcare sector.

Key Market Drivers

Enhanced Lab Efficiency

Market Overview
Forecast Period2024-2028
Market Size 2022USD 0.93 Billion
Market Size 2028USD 1.65 Billion
CAGR 2023-202810.19%
Fastest Growing SegmentDisease Diagnosis
Largest MarketNorth America

Digital pathology enhances efficiency by reducing turnaround time, lowering costs, and delivering comprehensive details to users with subject-matter expertise. Enhancing laboratory results is crucial as physicians and patients rely heavily on them for disease diagnosis and treatment. Digital pathology allows for rapid and remote access to pathology images, enabling faster collaboration among healthcare professionals. Pathologists and experts can review cases and provide consultations without the constraints of physical distance, potentially leading to quicker diagnosis and treatment decisions. Traditional pathology involves preparing and transporting physical slides, which can be time-consuming and costly. With digital pathology, there is a reduction in expenses related to slide production, shipping, storage, and retrieval. The increasing demand for accurate, efficient, and prompt laboratory results is fueling the growth of the digital pathology market.

Rapid Technological Advancements

Rapid advancements in digital pathology systems are anticipated to fuel market growth. Digital imaging, computerization, robotic light microscopy, and fiber optic communications all play a significant role in this expansion. Whole slide imaging, a technique with numerous advantages over conventional light microscopes, is projected to positively impact the market. Moreover, the development of microarrays and a wide range of predictive models, such as hybrid models and API algorithms, is anticipated to further accelerate market growth for digital image analysis. The increasing preference for computer-aided diagnosis, which integrates image processing, physics, mathematics, and computational algorithms, facilitates efficient disease detection and enables the assessment of anatomical structures of interest, disease progression, and risk assessment.

Rising Use of AI In Healthcare

The utilization of AI in healthcare is on the rise, with a growing focus on enhancing patient care quality through the integration of AI in different healthcare services, including pathological diagnosis. AI algorithms can analyze large volumes of pathology images quickly and accurately. They can assist pathologists in detecting abnormalities, identifying patterns, and providing more precise diagnoses, ultimately leading to faster treatment decisions and improved patient outcomes. AI can help mitigate human errors and variability in pathological diagnosis by providing objective and consistent analyses. This is especially valuable for complex cases where subtle features might be missed. By integrating patient data with AI insights, pathologists and clinicians can tailor treatment plans to individual patients, optimizing therapeutic approaches and minimizing unnecessary interventions. Consequently, artificial intelligence (AI) facilitates streamlined primary care processes and automation, enabling physicians to prioritize patients with more critical conditions. Additionally, AI solutions in the healthcare industry are progressively adopting a more human-centered approach.

Increasing Prevalence of Cancer

According to the World Health Organization, there were an unprecedented 9.6 million deaths and 18.1 million new cancer cases recorded worldwide in 2018. The increasing aging population and sedentary lifestyles globally are contributing to the rising number of cancer cases. The UN organization predicts that the number of older persons will reach nearly 2.1 billion by 2050. Preclinical research using animal models and clinical trials plays a vital role in determining the safety and efficacy of drugs. Digital pathology offers multiple benefits, such as reducing the risk of error, storing drug data, integrating data into electronic health records (EHRS), and assessing patient reactions to specific medications. The global digital pathology industry is experiencing growth due to the increasing focus on drug development and drug discovery research and development, leading to a rise in clinical and preclinical trials. The demand for faster diagnostic tools for chronic diseases like cancer and the need to enhance workflow productivity are driving factors. Additionally, the growing geriatric population, which is more susceptible to chronic conditions, is expected to further increase the demand for advanced technical diagnostic procedures.

Key Market Challenges

High Cost of Digital Pathology

The high cost of digital pathology and the low adoption rate in emerging and underdeveloped countries present obstacles to the market's growth. Augmenting addresses this challenge by offering a modular hardware platform with integrated digital pathology software applications, helping to keep costs low. Implementing digital pathology systems requires significant upfront investment in scanners, storage infrastructure, and software solutions. The expenses associated with digitizing slides, maintaining digital archives, and training personnel can be substantial, especially for small laboratories or healthcare facilities with limited budgets. Furthermore, integrating digital pathology into existing laboratory workflows and the need for IT support and infrastructure upgrades can pose challenges for some organizations.

Regulatory and Standardization Challenges

The adoption of digital pathology is influenced by regulatory requirements and standards that vary across different regions. The validation and regulatory approval of digital pathology systems and software can be a complex and time-consuming process. Additionally, addressing challenges related to data privacy, security, and compliance with patient confidentiality regulations during the transmission and storage of digital pathology images is crucial. Before digital pathology solutions can be used for clinical diagnosis, they often need to undergo rigorous validation processes to demonstrate their accuracy, reliability, and safety. Regulatory authorities in different regions may have varying criteria for approving these technologies. Patient data security and privacy are paramount in healthcare. Digital pathology systems must adhere to strict data protection regulations, such as the Health Insurance Portability and Accountability Act (HIPAA) in the United States and the General Data Protection Regulation (GDPR) in the European Union.

Key Market Trends

Telepathology and Remote Consultation

The increasing adoption of telepathology enables remote diagnosis and consultation, allowing pathologists to collaborate and provide expert opinions without being limited by geographical constraints. Telepathology has gained significant prominence during the COVID-19 pandemic, as it facilitates remote working and minimizes the risk of exposure for pathologists. For instance, pathologists can remotely review and discuss cases with colleagues, participate in multidisciplinary tumor boards, or offer consultations to underserved areas or regions facing a shortage of pathology expertise. The increasing preference for computer-aided diagnosis, integrating image processing, physics, mathematics, and computing algorithms, facilitates efficient disease detection. It also assists in evaluating anatomic structures of interest, quantifying disease progression, and risk assessment, thereby stimulating market growth. Notably, companies like Olympus offer a range of tools for remote slide sharing and image processing, contributing to anticipated market expansion in the upcoming years. In April 2020, Leica Biosystems obtained FDA approval for the Aperio AT2 DX Scanner and Aperio WebViewer, enabling remote diagnosis during the pandemic. Additionally, during this emergency, Phillips also received FDA approval for its IntelliSite Pathology Solution, further supporting remote diagnosis.

Analytics Integration of Artificial Intelligence and Machine Learning

The incorporation of Artificial Intelligence (AI) and machine learning algorithms into digital pathology platforms is a significant and emerging trend. AI has the capability to assist pathologists in various tasks, including automated tissue recognition, anomaly detection, biomarker quantification, and disease outcome prediction. These technologies hold great potential in enhancing efficiency, accuracy, and reproducibility in pathology diagnosis. For example, AI algorithms can aid in the automated detection and classification of cancer cells, as well as the identification of specific features in histopathological images.

Segmental Insights

Application Insights

The disease diagnostic segment is anticipated to witness significant growth during the forecast period due to the increasing prevalence of chronic diseases. Digital pathology encompasses a range of technologies for disease diagnosis, including laboratory management systems, digital dictation, dashboards and workflow control, digital image analysis, electronic specimen labeling and monitoring, and synoptic reporting tools. Manufacturers are currently focused on the development of novel and rapid diagnostic techniques. The integration of digital technology enhances every phase of the diagnostic process and facilitates seamless information exchange within and between departments.

End User Insights

The pharmaceutical and biotechnology companies represent the largest portion of global digital pathology demand by end-users. The significant share and rapid growth rate of this segment can be attributed to various factors. These include the increasing utilization of digital pathology in drug discovery studies and drug toxicology research. Additionally, biotechnology corporations leverage digital pathology for the development of biobanking, biopharmaceutical trials, molecular assays, and personalized medicine.

Regional Insights

North America holds the largest market share attributed to continuous R&D investments, government initiatives supporting technologically advanced systems, growing adoption of digital imaging, and the involvement of prominent players. In North America, the United States emerges as the market leader, driven by companies focusing on digital pathology research and the development of enhanced tools for image analysis. The accelerated use of digital pathology for disease diagnosis, coupled with favorable reimbursement policies in the U.S., is expected to drive regional growth and enhance the standard of cancer diagnosis. The increasing implementation of digital pathology in education and training, along with the integration of AI into digital pathology systems, are key factors propelling regional market growth.

The growth of the European market is fueled by increasing support for digital pathology projects, education, and training programs. Factors such as the rising incidence of cancer, the growing adoption of digital pathology solutions in the United Kingdom, and the increasing number of conferences in Germany also contribute to this growth. Digital pathology involves scanning glass slides to generate virtual images, which, along with clinical data, provide an integrated picture of cancer patients for pathologists. This enables additional diagnostic procedures, including image analysis studies, which are not possible with conventional glass slides. The United Kingdom shows a high adoption rate of digital pathology, with further expansion expected in the coming years. Moreover, pathologists in the United Kingdom express a need for guidance, training, and education on digital pathology solutions. With the increasing incidence of cancer in the United Kingdom, the digital pathology market in the country is projected to expand during the forecast period.

Key Market Players

  • 3DHISTECH
  • Corista
  • Aiforia Technologies Oy
  • Akoya Biosciences
  • OptraSCAN
  • Glencoe Software
  • QProscia Inc
  • Kanteron Systems
  • Mikroscan Technologies

Report Scope:

In this report, the Global Digital Pathology Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Digital Pathology Market, By Product Type:

  • Scanners
  • Software
  • Storage & Communication Systems

Digital Pathology Market, By Application:

  • Disease Diagnosis
  • Teleconsultation
  • Drug Discovery
  • Training & Education

Digital Pathology Market, By End User:

  • Pharmaceutical & Biotechnology Companies
  • Hospitals and Clinics
  • Academic Institutes & Research Laboratories

Digital Pathology Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait
    • Turkey
    • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Digital Pathology Market.

Available Customizations:

Global Digital Pathology market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer

5. Global Digital Pathology Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type (Scanners, Software, and Storage & Communication Systems)
    • 5.2.2. By Application (Disease Diagnosis, Teleconsultation, Drug Discovery, Training & Education)
    • 5.2.3. By End User (Pharmaceutical & Biotechnology Companies, Hospitals and Clinics, Academic Institutes & Research Laboratories)
    • 5.2.4. By Region
    • 5.2.5. By Company (2022)
  • 5.3. Market Map

6. North America Digital Pathology Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Application
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Digital Pathology Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Digital Pathology Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Digital Pathology Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By End User

7. Europe Digital Pathology Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Application
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Digital Pathology Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By End User
    • 7.3.2. United Kingdom Digital Pathology Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By End User
    • 7.3.3. Italy Digital Pathology Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By End User
    • 7.3.4. France Digital Pathology Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Type
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Digital Pathology Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Type
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By End User

8. Asia-Pacific Digital Pathology Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Application
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Digital Pathology Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By End User
    • 8.3.2. India Digital Pathology Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Digital Pathology Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Digital Pathology Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product Type
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Digital Pathology Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product Type
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By End User

9. South America Digital Pathology Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Application
    • 9.2.3. By End User
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Digital Pathology Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By End User
    • 9.3.2. Argentina Digital Pathology Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By End User
    • 9.3.3. Colombia Digital Pathology Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By End User

10. Middle East and Africa Digital Pathology Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By Application
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Digital Pathology Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By End User
    • 10.3.2. Saudi Arabia Digital Pathology Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By End User
    • 10.3.3. UAE Digital Pathology Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By End User

11. Market Dynamics

12. Market Trends & Developments

13. Global Digital Pathology Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. Business Overview
  • 14.2. Application Offerings
  • 14.3. Recent Developments
  • 14.4. Key Personnel
  • 14.5. SWOT Analysis
    • 14.5.1. 3DHISTECH
    • 14.5.2. Corista
    • 14.5.3. Aiforia Technologies Oy
    • 14.5.4. Akoya Biosciences
    • 14.5.5. OptraSCAN
    • 14.5.6. Glencoe Software
    • 14.5.7. QProscia Inc
    • 14.5.8. Kanteron Systems
    • 14.5.9. Mikroscan Technologies

15. Strategic Recommendations

16. About Us & Disclaimer